Researchers Behind COVID-19 RECOVERY Trial Launch New Monkeypox Treatment Trial - SIGA Technologies (NASDAQ:SIGA)

The U.K.-based Oxford University researchers behind the COVID-19 treatment trial RECOVERY are back again, this time for a randomized controlled trial assessing SIGA Technologies Inc's SIGA smallpox treatment Tpoxx (tecovirimat) for monkeypox.
The National Institute For Health and Care Research (NIHR) has commissioned and funded the study with a £3.7 million award. The first patients have now been recruited.
The FDA approved tecovirimat in 2018 for smallpox in adults and children. The CDC has been using an expanded access program for monkeypox.
Also Read: Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch.
And although the antiviral is only approved as a smallpox treatment, its FDA approval was based on studies in nonhuman primates infected with monkeypox.
The trial of tecovirimat in non-hospitalized monkeypox patients will test the efficacy and safety of tecovirimat for monkeypox.
The trial is looking to enroll about 500 participants. The trial will test 600 mg of tecovirimat twice daily for 14 days versus a placebo.
Price Action: SIGA shares are down 4.80% at $21.21 on the last check Tuesday.